Liquidia Corporation

Liquidia Corporation company information, Employees & Contact Information

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. Liquidia has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia is also developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, for use in North America. The subsidiary Liquidia PAH provides for the commercialization of pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection.

Company Details

Employees
190
Founded
-
Address
419 Davis Drive, Suite 100, Morrisville,nc 27560,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Morrisville, NC
Looking for a particular Liquidia Corporation employee's phone or email?

Liquidia Corporation Questions

News

Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025 - GlobeNewswire

Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025 GlobeNewswire

Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025 - Quiver Quantitative

Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025 Quiver Quantitative

Oct. 28 R&D Day — Liquidia to present L606 sustained‑release and YUTREPIA clinical update; webcast - Stock Titan

Oct. 28 R&D Day — Liquidia to present L606 sustained‑release and YUTREPIA clinical update; webcast Stock Titan

Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference - Yahoo Finance

Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference Yahoo Finance

Liquidia Corporation Announces First Research & Development Day Focusing on Innovative Therapies for Pulmonary Hypertension - Quiver Quantitative

Liquidia Corporation Announces First Research & Development Day Focusing on Innovative Therapies for Pulmonary Hypertension Quiver Quantitative

Breaking PH-ILD Research: Liquidia's LIQ861 16-Week Trial Data to be Revealed at Major CHEST Conference - Stock Titan

Breaking PH-ILD Research: Liquidia's LIQ861 16-Week Trial Data to be Revealed at Major CHEST Conference Stock Titan

Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 - GlobeNewswire

Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 GlobeNewswire

Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance

Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update Yahoo Finance

Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12 - Quiver Quantitative

Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12 Quiver Quantitative

Breaking PH-ILD Treatment Data: Liquidia's YUTREPIA Shows New Safety Results in ASCENT Trial at PHPN - Stock Titan

Breaking PH-ILD Treatment Data: Liquidia's YUTREPIA Shows New Safety Results in ASCENT Trial at PHPN Stock Titan

Liquidia Corporation to Present New Data on LIQ861 at Pulmonary Hypertension Professional Association Symposium - Quiver Quantitative

Liquidia Corporation to Present New Data on LIQ861 at Pulmonary Hypertension Professional Association Symposium Quiver Quantitative

Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting - GlobeNewswire

Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting GlobeNewswire

Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium - GlobeNewswire

Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium GlobeNewswire

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD - Yahoo Finance

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD Yahoo Finance

Biotech Developer Liquidia Corporation Set for Key Investor Presentation at Wells Fargo Healthcare Conference - Stock Titan

Biotech Developer Liquidia Corporation Set for Key Investor Presentation at Wells Fargo Healthcare Conference Stock Titan

Liquidia Executive Team to Reveal Latest Business Developments at Major Healthcare Conference - Stock Titan

Liquidia Executive Team to Reveal Latest Business Developments at Major Healthcare Conference Stock Titan

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - GlobeNewswire

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics GlobeNewswire

Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update GlobeNewswire

Liquidia Corporation Provides Corporate Update and Financial Results Ahead of May 24 FDA Decision on YUTREPIA™ NDA - Quiver Quantitative

Liquidia Corporation Provides Corporate Update and Financial Results Ahead of May 24 FDA Decision on YUTREPIA™ NDA Quiver Quantitative

Liquidia Corporation Strengthens Financial Position by - GlobeNewswire

Liquidia Corporation Strengthens Financial Position by GlobeNewswire

United Therapeutics Files Patent Infringement Lawsuit Against Liquidia Over YUTREPIA™ Inhalation Powder - Quiver Quantitative

United Therapeutics Files Patent Infringement Lawsuit Against Liquidia Over YUTREPIA™ Inhalation Powder Quiver Quantitative

Liquidia Corporation Announces FDA Acceptance of New Drug - GlobeNewswire

Liquidia Corporation Announces FDA Acceptance of New Drug GlobeNewswire

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - Stock Titan

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics Stock Titan

Breakthrough FDA Approval: YUTREPIA's Novel Dry-Powder Tech Targets 105,000 PAH and PH-ILD Patients - Stock Titan

Breakthrough FDA Approval: YUTREPIA's Novel Dry-Powder Tech Targets 105,000 PAH and PH-ILD Patients Stock Titan

Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update GlobeNewswire

Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606) - GlobeNewswire

Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606) GlobeNewswire

Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions - Stock Titan

Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions Stock Titan

United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent - GlobeNewswire

United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent GlobeNewswire

Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023 - GlobeNewswire

Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023 GlobeNewswire

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder - Stock Titan

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder Stock Titan

Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder - Yahoo Finance

Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder Yahoo Finance

Liquidia Appoints Rajeev Saggar, M.D., as Chief Medical Officer - citybiz

Liquidia Appoints Rajeev Saggar, M.D., as Chief Medical Officer citybiz

Liquidia Appoints Roger Jeffs CEO - citybiz

Liquidia Appoints Roger Jeffs CEO citybiz

LQDA - Liquidia Corporation Latest Stock News & Market Updates - Stock Titan

LQDA - Liquidia Corporation Latest Stock News & Market Updates Stock Titan

Top Liquidia Corporation Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant